Vistaril and Metastases to bone - a phase IV clinical study of FDA data

Summary:

Metastases to bone is reported as a side effect among people who take Vistaril (hydroxyzine hydrochloride), especially for people who are female, 60+ old, also take Zometa, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Metastases to bone when taking Vistaril. It is created by eHealthMe based on reports of 8,641 people who have side effects when taking Vistaril from the FDA, and is updated regularly.

What is Vistaril?

Vistaril has active ingredients of hydroxyzine hydrochloride. It is often used in stress and anxiety. eHealthMe is studying from 9,565 Vistaril users. Check the latest studies of Vistaril.

What is Metastases to bone?

Metastases to bone (cancer spreads to bone) is found to be associated with 1,126 drugs and 902 conditions by eHealthMe. Check the latest studies of Metastases to bone.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 15, 2026

8,641 people reported to have side effects when taking Vistaril.
Among them, 39 people (0.45%) have Metastases to bone.

Could Vistaril cause Metastases to bone?

Among these 39 people:

What is the gender of people who have Metastases to bone when taking Vistaril? *

female: 58.97 %
male: 41.03 %

What is the age of people who have Metastases to bone when taking Vistaril? *

What are other drugs people take besides Vistaril? *

What are other side effects people have besides Metastases to bone? *

Pain: 37 people, 94.87%
Osteonecrosis Of Jaw (death of bone of jaw): 35 people, 89.74%
Pleural Effusion (water on the lungs): 29 people, 74.36%
Deformity (disfigurement): 28 people, 71.79%
Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 26 people, 66.67%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 22 people, 56.41%
Bone Disorder: 22 people, 56.41%
Rashes (redness): 21 people, 53.85%
Primary Sequestrum (piece of dead bone that has become separated during the process of necrosis from normal/sound bone): 21 people, 53.85%
Dehydration (dryness resulting from the removal of water): 21 people, 53.85%

What are the existing conditions these people have? *

Breast Cancer: 12 people, 30.77%
Breast Cancer Metastatic: 12 people, 30.77%
Neoplasm Malignant (cancer tumour): 11 people, 28.21%
High Blood Cholesterol: 7 people, 17.95%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 6 people, 15.38%
High Blood Pressure: 6 people, 15.38%
Depression: 3 people, 7.69%
Bipolar Disorder (mood disorder): 2 people, 5.13%
Thyroid Diseases: 1 person, 2.56%
Bone Pain: 1 person, 2.56%

* Approximation only. Some reports may have incomplete information.

Do you take Vistaril and have Metastases to bone?

- Check whether Metastases to bone is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Vistaril:

Vistaril (9,565 reports)

Browse all side effects of Vistaril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Metastases to bone:

Metastases to bone (1,126 drugs)

Browse all the conditions that are associated with Metastases to bone:

Metastases to bone (902 conditions)

Related publications that referenced our studies

Ate? ?, Arikan MF, Kaplan M, Altay M, "Hydroxyzine induced pancytopenia and petechial rashes: a rare complication", Journal Of Contemporary Medicine, 2017 Jan .
Ate? ?, Arikan MF, Kaplan M, Altay M, "Hydroxyzine induced pancytopenia and petechial rashes: a rare complication", Journal Of Contemporary Medicine, 2017 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on hydroxyzine hydrochloride (the active ingredients of Vistaril) and Vistaril (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.